The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Covaxin is not approved in the USA for any age group
Subscribe To Our Newsletter & Stay Updated
